Drug intelligence / Profile preview

CD3xEpCAM bispecific antibody

Development stage: Unknown
Lead developer: Amgen
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

The CD3xEpCAM bispecific antibody is designed to target both CD3 on T cells and EpCAM on epithelial tumor cells. It acts by engaging and activating T cells to kill tumor cells, primarily used in the treatment of epithelial cancers such as colorectal, ovarian, and breast cancer. The mechanism involves forming a cytolytic synapse between T cells and tumor cells, leading to the release of cytotoxic granules and tumor cell lysis.

Other names: CD3×EpCAM BsAbanti-EpCAM × anti-CD3 bispecific antibodyEpCAM/CD3-bispecific T-cell engagerEpCAM × CD3 T-cell engager

Targets

EPCAM (Epithelial cell adhesion molecule)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on CD3xEpCAM bispecific antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD3xEpCAM bispecific antibody.

Explore the full profile